145P Immune-competent 3D InSightTM tumour models as novel platform to assess combinatorial biologics therapy

ConclusionOur 3D InSightTM tumour models can be successfully employed for optimal high throughput screening of biologics to unveil the efficacy and anti-tumour properties of immune-targeting therapeutic agents.Legal entity responsible for the studyInSphero.FundingInSphero AG.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research